Renin-angiotensin blockade and kidney disease.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

13 citing papers in PubMed.

1. Prescription of ACE-Is/ARBs in patients with cardio-renal disease: a multicenter retrospective cohort study from the REPOSI registry.Internal and emergency medicine · 2025
   Observational
2. Aliskiren improves renal morphophysiology and inflammation in Wistar rats with 2K1C renovascular hypertension.Histology and histopathology · 2020
   Article
3. Vitamin D and Metabolic Diseases: Growing Roles of Vitamin D.Journal of obesity & metabolic syndrome · 2018
   Review
4. The Beneficial Effects of Allicin in Chronic Kidney Disease Are Comparable to Losartan.International journal of molecular sciences · 2017
   Article
5. Cross-talk between AMP-activated protein kinase and renin-angiotensin system in uninephrectomised rats.Journal of the renin-angiotensin-aldosterone system : JRAAS · 2016
   Article
6. Identification and management of albuminuria in the primary care setting.Journal of clinical hypertension (Greenwich, Conn.) · 2011
   Review
7. Common secondary causes of resistant hypertension and rational for treatment.International journal of hypertension · 2011
   Article
8. Application of direct renin inhibition to chronic kidney disease.Cardiovascular drugs and therapy · 2010
   Review
9. Addressing the theoretical and clinical advantages of combination therapy with inhibitors of the renin-angiotensin-aldosterone system: antihypertensive effects and benefits beyond BP control.Life sciences · 2010
   Review
10. Role of the intrarenal renin-angiotensin-aldosterone system in chronic kidney disease.American journal of nephrology · 2010
    Review
11. The current state of RAAS blockade in the treatment of hypertension and proteinuria.Current cardiology reports · 2009
    Review
12. Should albuminuria be a focus of antihypertensive therapy goals?Current hypertension reports · 2009
    Review
13. Uncritical acceptance of combination treatment of angiotensin II receptor blocker and angiotensin-converting enzyme inhibitor in nondiabetic renal disease trial results.Hypertension (Dallas, Tex. : 1979) · 2009
    Article

Corrections and comments

• Comment on
  Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.2008

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as